The stock has not done well and struggles to meet earnings expectations. Management itself became frustrated and put themselves up for strategic sale. It is worth holding to see what the reviews will be, but would not be a new buyer.

This is a top 5 company in the pipeline group. Dividend stocks are getting hurt by the fear of rising interest rates. This is a great company with a good record of increasing dividends. This is just the wrong sector right now. He would still hold it for the long term for diversification. Yield 5.3%.

They do recommend it in one of their portfolios. The health monitoring business is growing and he would like to see more contracts signed. There are risks as this has a high valuation. He likes the management team. It is a speculative buy.

This was a split-off company who struggles with a small market cap. He does not recommend this one. (Analysts’ price target is $0.35 )

This is a cannabis company that has a new product line for pets. He generally dislikes the sector and the associated valuations. You are betting this sector is going to explode and it is hard to know which companies will survive. It has a $600 million valuation on $20 million in sales.

This cannabis company has an advantage with its size. If they have started to make other acquisitions they can grow with scale. Their deal with Constellation Brands will allow them to grow internationally. Its valuation is just too high for him.

Costs are going up and revenues are going down. They have done many stock issues and not rewarded their investors. When production forecasts fall short of expectations investors will go elsewhere.